ArticleFrontiers in medicine2025
Feasibility of data extraction and evaluation with BeoNet-Halle: outcomes and data quality in hepatitis B and C screenings.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To support the global hepatitis strategy, the Federal Joint Committee in Germany introduced a one-time hepatitis screening within the "Check-Up 35" program on 1 October 2021. Targeting individuals aged 35 and older, this preventive check-up aims to detect common diseases early. This study examines the feasibility of using the BeoNet-Halle database to characterize patients screened for hepatitis B (HBV) and hepatitis C virus (HCV), focusing on screening volumes, billing codes, and data completeness. Methods: We analyzed electronic medical records from all 11 practices contributing to the BeoNet network during the observation period from 1 October 2021 to 30 September 2023. The analysis focused on antibody and antigen tests, HBV-DNA and HCV-RNA tests, and billing codes (01734, 01744, 01865, 01866, 01867) to assess screening volumes, data completeness, and costs. Data completeness was evaluated by mapping the BeoNet dataset to the Medical Informatics Initiative (MII) Core Dataset. Results: Of the potentially eligible population (32,213 patients aged ≥ 35), 10% underwent HBV and HCV screening as part of Check-Up 35. Screened individuals had more practice contacts (mean ± SD: 22.1 ± 19.8 vs. 11.1 ± 17.7; w = 0.3) and more chronic conditions (mean ± SD: 6.9 ± 5.6 vs. 5.8 ± 6.2; w = 0.03) than the eligible practice population. Screening identified 20 new cases (0.6%), with practice-level screening rates ranging from 2.5% to 42.6%. Billing code 01734 was documented in 81.5% of cases with laboratory test billing codes (01865-01867) missing in 5 of the 11 practice management systems (PMS). The BeoNet laboratory dataset provided full coverage for test identifiers (100%) and strong documentation of result interpretations (98.7%), but had limited coverage for reference range (60.4%) and test collection dates (9.1%). Conclusion: Improving data quality and billing documentation in the BeoNet database could enhance screening accuracy and resource allocation, supporting better outcomes in hepatitis screening practices.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.